Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8126109 | 0.95 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1HSD17B10TDP1 | |
| SCHEMBL6855472 | 0.88 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1HSD17B10TDP1 | |
| SCHEMBL4672067 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11HSD17B10ITGB3ITGA2B | |
| SCHEMBL5839879 | 0.80 | ESR1 (0.56) | CYP4F2CYP4A11ITGB3ITGA2BHDAC3 | |
| SCHEMBL16381954 | 0.80 | ALDH1A1 (0.42) | CYP4F2CYP4A11ALDH1A1HSD17B10TDP1 | |
| SCHEMBL1064265 | 0.79 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1HDAC3HDAC1 | |
| SCHEMBL6028281 | 0.79 | CYP4F2 (0.44) | CYP4F2CYP4A11ITGB3ITGA2BHDAC3 | |
| SCHEMBL26413056 | 0.79 | MLNR (0.50) | CYP4F2CYP4A11ALDH1A1HDAC3HDAC1 | |
| SCHEMBL430182 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11ALDH1A1HSD17B10ITGB3 | |
| SCHEMBL15447468 | 0.79 | CYP4F2 (0.44) | CYP4F2CYP4A11ITGB3ITGA2BHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797714-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | BAYER PHARMACEUTICALS CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-6469031-B1 | USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS | BAYER CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-1040106-B1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | BAYER AG (US) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | CYP4F2 1328/4885CYP4A11 301/4885ALDH1A1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.